Emberton M - Search Results

1

"TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now.

Grummet J, Gorin MA, Popert R, O'Brien T, Lamb AD, Hadaschik B, Radtke JP, Wagenlehner F, Baco E, Moore CM, Emberton M, George AK, Davis JW, Szabo RJ, Buckley R, Loblaw A, Allaway M, Kastner C, Briers E, Royce PL, Frydenberg M, Murphy DG, Woo HH. Grummet J, et al. Among authors: emberton m. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):62-65. doi: 10.1038/s41391-020-0204-8. Epub 2020 Jan 13. Prostate Cancer Prostatic Dis. 2020. PMID: 31932659 Free PMC article. Review. No abstract available.

2

Classic papers in Urology.

Thomas K, Moore CM, Gerharz EW, O'Brien T, Emberton M. Thomas K, et al. Among authors: emberton m. Eur Urol. 2003 Jun;43(6):591-5. doi: 10.1016/s0302-2838(03)00143-x. Eur Urol. 2003. PMID: 12767357

3

Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer?

Moore CM, Hoh IM, Bown SG, Emberton M. Moore CM, et al. Among authors: emberton m. BJU Int. 2005 Oct;96(6):754-8. doi: 10.1111/j.1464-410X.2005.05709.x. BJU Int. 2005. PMID: 16153193 Review. No abstract available.

4

Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.

Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton M, Bown SG. Moore CM, et al. Among authors: emberton m. Lasers Surg Med. 2006 Jun;38(5):356-63. doi: 10.1002/lsm.20275. Lasers Surg Med. 2006. PMID: 16392142 Clinical Trial.

5

Point-of-care PSA testing: an evaluation of PSAwatch.

Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, Walker I, Davidson I. Karim O, et al. Among authors: emberton m. Prostate Cancer Prostatic Dis. 2007;10(3):270-3. doi: 10.1038/sj.pcan.4500962. Epub 2007 Mar 13. Prostate Cancer Prostatic Dis. 2007. PMID: 17353914

6

Photodynamic therapy for prostate cancer--a review of current status and future promise.

Moore CM, Pendse D, Emberton M. Moore CM, et al. Among authors: emberton m. Nat Clin Pract Urol. 2009 Jan;6(1):18-30. doi: 10.1038/ncpuro1274. Nat Clin Pract Urol. 2009. PMID: 19132003 Review.

7

Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer.

Ahmed HU, Moore C, Emberton M. Ahmed HU, et al. Among authors: emberton m. Surg Oncol. 2009 Sep;18(3):219-32. doi: 10.1016/j.suronc.2009.02.002. Epub 2009 Mar 5. Surg Oncol. 2009. PMID: 19268572 Review.

8

Life after prostate cancer. Time to evaluate focal therapy.

Cathcart P, Ahmed HU, Moore C, Emberton M. Cathcart P, et al. Among authors: emberton m. BMJ. 2010 Feb 23;340:c1057. doi: 10.1136/bmj.c1057. BMJ. 2010. PMID: 20179109 No abstract available.

9

Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy.

Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H, Freeman A, Allen C, Kirkham A, Emberton M. Arumainayagam N, et al. Among authors: emberton m. BJU Int. 2010 Oct;106(7):991-7. doi: 10.1111/j.1464-410X.2010.09291.x. Epub 2010 Mar 9. BJU Int. 2010. PMID: 20230392

10

Focal therapy in prostate cancer: determinants of success and failure.

Ahmed HU, Moore C, Lecornet E, Emberton M. Ahmed HU, et al. Among authors: emberton m. J Endourol. 2010 May;24(5):819-25. doi: 10.1089/end.2009.0665. J Endourol. 2010. PMID: 20380513

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

567 results

Search Page

Filters